Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DSHEA Sheds Little Light On Distinguishing Old From New Ingredients

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Senate staffer Patricia Knight, who helped write DSHEA, says her “one regret” about the law passed in 1994 is “something we left out, how to prove, how to lock in what was on the market.” There “is just no way for the FDA to figure out what was on the market then,” she says.

You may also be interested in...



Lack Of Supplement NDI Notification Guidance Not A Market Pass For Industry

Manufacturers, ingredient suppliers and other parties submitting NDI notifications can improve the industry's outlook by "anticipating future products that haven't been brought to market yet" and proposing the highest concentration of an ingredient for the broadest variety of uses, says ODSP senior advisory Cara Welch.

Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA

CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.

FDA Waits For NDI Notifications Increase On Tail Of 'No Objection' Uptick

FDA has seen an uptick in “acknowledgement with no objection” response letters to dietary supplement firms' s NDI notifications, but says those positive responses still account for only a quarter of all its responses.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel